BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesConference / presentation

SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern Time) on May 12, 2026 in Las Vegas.

Open original release

Related news

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

ANNXAnnexon, Inc.2026-05-06 12:00 EST

Annexon to Present at the Bank of America Securities Health Care Conference 2026

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

ABOSAcumen Pharmaceuticals2026-05-07 20:00 EST

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

TEVATeva Pharmaceutical Industries2026-05-04 20:30 EST

Teva to Present at the BofA Securities Health Care Conference

HRMYHarmony Biosciences2026-03-31 12:05 EST

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

ANNXAnnexon, Inc.2026-04-08 20:05 EST

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

View all latest news

Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, neurology, and endocrinology. Its commercial and development work centers on disorders with clear unmet need and durable treatment demand.

Recent company news

NBIXNeurocrine Biosciences2026-06-03 12:30 EST

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

NBIXNeurocrine Biosciences2026-05-18 20:05 EST

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

NBIXNeurocrine Biosciences2026-05-06 12:30 EST

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Stock data

Close
176.41 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States